Search results
Results from the WOW.Com Content Network
[9] [10] These drugs had been further developed prior to the COVID-19 pandemic for other diseases including SARS. [11] The utility of targeting the 3CL protease in a real world setting was first demonstrated in 2018 when GC376 (a prodrug of GC373) was used to treat the previously 100% lethal cat coronavirus disease, feline infectious ...
COVID-19: Merck & Co. viral RNA polymerase inhibitor Moroxydine: Influenza Nelfinavir: HIV Nirmatrelvir/ritonavir (Paxlovid) COVID-19: Pfizer: 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine: HIV non-nucleoside reverse transcriptase inhibitor: Nitazoxanide: Broad-spectrum antiviral ...
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
No participants had received a COVID‑19 vaccine or been previously infected with COVID‑19. [12] The main outcome measured in the trial was the proportion of people who were hospitalized due to COVID‑19 or died due to any cause during 28 days of follow-up. [12] EPIC-HR started in July 2021, and completed in December 2021. [49]
Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. [7] It is used to treat COVID‑19 in those infected by SARS-CoV-2. [7]
In the United States, remdesivir is indicated for the treatment of COVID‑19 in people 28 days of age and older and weighing at least 3 kilograms (6.6 lb) who are hospitalized; or not hospitalized and have mild-to-moderate COVID‑19, and are at high risk for progression to severe COVID‑19, including hospitalization or death. [12] [26]
COVID-19: candidate drug treatments in Phase III–IV trials Drug candidate Description Existing disease approval Trial sponsor(s) Location(s) Expected results Notes, references Remdesivir: antiviral; adenosine nucleotide analog inhibiting RNA synthesis in coronaviruses: investigational [33] Gilead, WHO, INSERM, NIAID
Image illustrates DNA, RNA, and protein synthesis. The first two are nucleic acids. A nucleic acid inhibitor is a type of antibacterial that acts by inhibiting the production of nucleic acids. There are two major classes: DNA inhibitors and RNA inhibitors. [1] The antifungal flucytosine acts in a similar manner.